Skip to main content
NCBI home page
Journal of Virology logoLink to Journal of Virology
. 1996 Aug;70(8):4884–4894. doi: 10.1128/jvi.70.8.4884-4894.1996

Frequency of multiple Epstein-Barr virus infections in T-cell-immunocompromised individuals.

Q Y Yao 1, R J Tierney 1, D Croom-Carter 1, D Dukers 1, G M Cooper 1, C J Ellis 1, M Rowe 1, A B Rickinson 1
PMCID: PMC190438  PMID: 8763991

Abstract

The Epstein-Barr virus (EBV) carrier state is characterized by latent infection of the general B-cell pool and by chronic virus replication at oropharyngeal sites. In Caucasian populations, most healthy carriers seem to harbor one dominant transforming virus strain, usually of type I rather than type 2, which persists over time and is detectable both in the blood and in the throat. This finding implies that once the virus carrier state is established, both viral reservoirs are largely if not completely protected from infection with additional strains. However, it is not known which facets of the immune response offer that protection. Here we address this question by a detailed study of EBV carriage in patients T-cell immunocompromised as a result of chronic human immunodeficiency virus (HIV) infection. Resident EBV strains were rescued from blood and from throat washings by using an in vitro transformation assay which aims to minimize bias toward faster-growing transformants; in this way, a mean of 16 independent isolations were made from each of 35 HIV-positive (predominantly male homosexual) patients. These virus isolates were characterized first at the DNA level by PCR amplification across type-specific polymorphisms in the EBNA2 and EBNA3C genes and across the 30-bp deletion and 33-bp repeat loci in the LMP1 gene and then at the protein level by immunoblotting for the strain-specific "EBNAprint" of EBNA1, -2, and -3C molecular weights. By these criteria, 18 of 35 patients harbored only one detectable EBV strain, usually of type 1, as do healthy carriers. However, the other 17 patients showed clear evidence of multiple infection with different EBV strains. In eight cases these strains were of the same type, again usually type 1, and were more often found coresident in throat washings than in the blood. By contrast, a further nine patients gave evidence of coinfection with type 1 and type 2 strains, and in these cases both virus types were detectable in the blood as well as in the throat. Immunological assays on these HIV-positive patients as a group showed a marked impairment of T-cell responses, reflected in reduced levels of EBV-specific cytotoxic T-cell memory, but an elevation of humoral responses, reflected in raised antibody titers to the EBV envelope glycoprotein gp340 and by the maintenance of virus neutralizing antibodies in serum. We infer that selective impairment of the T-cell system predisposes the host to infection with additional exogenously transmitted EBV strains.

Full Text

The Full Text of this article is available as a PDF (945.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abdel-Hamid M., Chen J. J., Constantine N., Massoud M., Raab-Traub N. EBV strain variation: geographical distribution and relation to disease state. Virology. 1992 Sep;190(1):168–175. doi: 10.1016/0042-6822(92)91202-6. [DOI] [PubMed] [Google Scholar]
  2. Adldinger H. K., Delius H., Freese U. K., Clarke J., Bornkamm G. W. A putative transforming gene of Jijoye virus differs from that of Epstein-Barr virus prototypes. Virology. 1985 Mar;141(2):221–234. doi: 10.1016/0042-6822(85)90253-3. [DOI] [PubMed] [Google Scholar]
  3. Aitken C., Sengupta S. K., Aedes C., Moss D. J., Sculley T. B. Heterogeneity within the Epstein-Barr virus nuclear antigen 2 gene in different strains of Epstein-Barr virus. J Gen Virol. 1994 Jan;75(Pt 1):95–100. doi: 10.1099/0022-1317-75-1-95. [DOI] [PubMed] [Google Scholar]
  4. Alfieri C., Joncas J. H. Biomolecular analysis of a defective nontransforming Epstein-Barr virus (EBV) from a patient with chronic active EBV infection. J Virol. 1987 Oct;61(10):3306–3309. doi: 10.1128/jvi.61.10.3306-3309.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Anagnostopoulos I., Hummel M., Kreschel C., Stein H. Morphology, immunophenotype, and distribution of latently and/or productively Epstein-Barr virus-infected cells in acute infectious mononucleosis: implications for the interindividual infection route of Epstein-Barr virus. Blood. 1995 Feb 1;85(3):744–750. [PubMed] [Google Scholar]
  6. Apolloni A., Sculley T. B. Detection of A-type and B-type Epstein-Barr virus in throat washings and lymphocytes. Virology. 1994 Aug 1;202(2):978–981. doi: 10.1006/viro.1994.1422. [DOI] [PubMed] [Google Scholar]
  7. Baer R., Bankier A. T., Biggin M. D., Deininger P. L., Farrell P. J., Gibson T. J., Hatfull G., Hudson G. S., Satchwell S. C., Séguin C. DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature. 1984 Jul 19;310(5974):207–211. doi: 10.1038/310207a0. [DOI] [PubMed] [Google Scholar]
  8. Ball M. J., Griffiths D. Effect on chemical analyses of beta-propiolactone treatment of whole blood and plasma. Lancet. 1985 May 18;1(8438):1160–1161. doi: 10.1016/s0140-6736(85)92465-1. [DOI] [PubMed] [Google Scholar]
  9. Boyle M. J., Sewell W. A., Sculley T. B., Apolloni A., Turner J. J., Swanson C. E., Penny R., Cooper D. A. Subtypes of Epstein-Barr virus in human immunodeficiency virus-associated non-Hodgkin lymphoma. Blood. 1991 Dec 1;78(11):3004–3011. [PubMed] [Google Scholar]
  10. Buisson M., Morand P., Genoulaz O., Bourgeat M. J., Micoud M., Seigneurin J. M. Changes in the dominant Epstein-Barr virus type during human immunodeficiency virus infection. J Gen Virol. 1994 Feb;75(Pt 2):431–437. doi: 10.1099/0022-1317-75-2-431. [DOI] [PubMed] [Google Scholar]
  11. Burrows S. R., Sculley T. B., Misko I. S., Schmidt C., Moss D. J. An Epstein-Barr virus-specific cytotoxic T cell epitope in EBV nuclear antigen 3 (EBNA 3). J Exp Med. 1990 Jan 1;171(1):345–349. doi: 10.1084/jem.171.1.345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Dambaugh T., Hennessy K., Chamnankit L., Kieff E. U2 region of Epstein-Barr virus DNA may encode Epstein-Barr nuclear antigen 2. Proc Natl Acad Sci U S A. 1984 Dec;81(23):7632–7636. doi: 10.1073/pnas.81.23.7632. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Falk K., Gratama J. W., Rowe M., Zou J. Z., Khanim F., Young L. S., Oosterveer M. A., Ernberg I. The role of repetitive DNA sequences in the size variation of Epstein-Barr virus (EBV) nuclear antigens, and the identification of different EBV isolates using RFLP and PCR analysis. J Gen Virol. 1995 Apr;76(Pt 4):779–790. doi: 10.1099/0022-1317-76-4-779. [DOI] [PubMed] [Google Scholar]
  14. Frank D., Cesarman E., Liu Y. F., Michler R. E., Knowles D. M. Posttransplantation lymphoproliferative disorders frequently contain type A and not type B Epstein-Barr virus. Blood. 1995 Mar 1;85(5):1396–1403. [PubMed] [Google Scholar]
  15. Gavioli R., Kurilla M. G., de Campos-Lima P. O., Wallace L. E., Dolcetti R., Murray R. J., Rickinson A. B., Masucci M. G. Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4. J Virol. 1993 Mar;67(3):1572–1578. doi: 10.1128/jvi.67.3.1572-1578.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Gratama J. W., Lennette E. T., Lönnqvist B., Oosterveer M. A., Klein G., Ringdén O., Ernberg I. Detection of multiple Epstein-Barr viral strains in allogeneic bone marrow transplant recipients. J Med Virol. 1992 May;37(1):39–47. doi: 10.1002/jmv.1890370107. [DOI] [PubMed] [Google Scholar]
  17. Gratama J. W., Oosterveer M. A., Klein G., Ernberg I. EBNA size polymorphism can be used to trace Epstein-Barr virus spread within families. J Virol. 1990 Oct;64(10):4703–4708. doi: 10.1128/jvi.64.10.4703-4708.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Gratama J. W., Oosterveer M. A., Weimar W., Sintnicolaas K., Sizoo W., Bolhuis R. L., Ernberg I. Detection of multiple 'Ebnotypes' in individual Epstein-Barr virus carriers following lymphocyte transformation by virus derived from peripheral blood and oropharynx. J Gen Virol. 1994 Jan;75(Pt 1):85–94. doi: 10.1099/0022-1317-75-1-85. [DOI] [PubMed] [Google Scholar]
  19. Gratama J. W., Oosterveer M. A., Zwaan F. E., Lepoutre J., Klein G., Ernberg I. Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: implications for sites of viral latency. Proc Natl Acad Sci U S A. 1988 Nov;85(22):8693–8696. doi: 10.1073/pnas.85.22.8693. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Greenspan J. S., Greenspan D., Lennette E. T., Abrams D. I., Conant M. A., Petersen V., Freese U. K. Replication of Epstein-Barr virus within the epithelial cells of oral "hairy" leukoplakia, an AIDS-associated lesion. N Engl J Med. 1985 Dec 19;313(25):1564–1571. doi: 10.1056/NEJM198512193132502. [DOI] [PubMed] [Google Scholar]
  21. Grässer F. A., Murray P. G., Kremmer E., Klein K., Remberger K., Feiden W., Reynolds G., Niedobitek G., Young L. S., Mueller-Lantzsch N. Monoclonal antibodies directed against the Epstein-Barr virus-encoded nuclear antigen 1 (EBNA1): immunohistologic detection of EBNA1 in the malignant cells of Hodgkin's disease. Blood. 1994 Dec 1;84(11):3792–3798. [PubMed] [Google Scholar]
  22. Kunimoto M., Tamura S., Tabata T., Yoshie O. One-step typing of Epstein-Barr virus by polymerase chain reaction: predominance of type 1 virus in Japan. J Gen Virol. 1992 Feb;73(Pt 2):455–461. doi: 10.1099/0022-1317-73-2-455. [DOI] [PubMed] [Google Scholar]
  23. Kyaw M. T., Hurren L., Evans L., Moss D. J., Cooper D. A., Benson E., Esmore D., Sculley T. B. Expression of B-type Epstein-Barr virus in HIV-infected patients and cardiac transplant recipients. AIDS Res Hum Retroviruses. 1992 Nov;8(11):1869–1874. doi: 10.1089/aid.1992.8.1869. [DOI] [PubMed] [Google Scholar]
  24. Lee S. P., Thomas W. A., Murray R. J., Khanim F., Kaur S., Young L. S., Rowe M., Kurilla M., Rickinson A. B. HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. J Virol. 1993 Dec;67(12):7428–7435. doi: 10.1128/jvi.67.12.7428-7435.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Lung M. L., Lam W. P., Sham J., Choy D., Yong-Sheng Z., Guo H. Y., Ng M. H. Detection and prevalence of the "f" variant of Epstein-Barr virus in southern China. Virology. 1991 Nov;185(1):67–71. doi: 10.1016/0042-6822(91)90754-y. [DOI] [PubMed] [Google Scholar]
  26. Luxton J. C., Williams I., Weller I., Crawford D. H. Epstein-Barr virus infection of HIV-seropositive individuals is transiently suppressed by high-dose acyclovir treatment. AIDS. 1993 Oct;7(10):1337–1343. doi: 10.1097/00002030-199310000-00006. [DOI] [PubMed] [Google Scholar]
  27. Maunders M. J., Petti L., Rowe M. Precipitation of the Epstein-Barr virus protein EBNA 2 by an EBNA 3c-specific monoclonal antibody. J Gen Virol. 1994 Apr;75(Pt 4):769–778. doi: 10.1099/0022-1317-75-4-769. [DOI] [PubMed] [Google Scholar]
  28. Miller W. E., Edwards R. H., Walling D. M., Raab-Traub N. Sequence variation in the Epstein-Barr virus latent membrane protein 1. J Gen Virol. 1994 Oct;75(Pt 10):2729–2740. doi: 10.1099/0022-1317-75-10-2729. [DOI] [PubMed] [Google Scholar]
  29. Nilsson K., Klein G., Henle W., Henle G. The establishment of lymphoblastoid lines from adult and fetal human lymphoid tissue and its dependence on EBV. Int J Cancer. 1971 Nov 15;8(3):443–450. doi: 10.1002/ijc.2910080312. [DOI] [PubMed] [Google Scholar]
  30. Rahman M. A., Kingsley L. A., Breinig M. K., Ho M., Armstrong J. A., Atchison R. W., Lyter D. W., Rinaldo C. R., Jr Enhanced antibody responses to Epstein-Barr virus in HIV-infected homosexual men. J Infect Dis. 1989 Mar;159(3):472–479. doi: 10.1093/infdis/159.3.472. [DOI] [PubMed] [Google Scholar]
  31. Rickinson A. B., Moss D. J., Wallace L. E., Rowe M., Misko I. S., Epstein M. A., Pope J. H. Long-term T-cell-mediated immunity to Epstein-Barr virus. Cancer Res. 1981 Nov;41(11 Pt 1):4216–4221. [PubMed] [Google Scholar]
  32. Rickinson A. B., Young L. S., Rowe M. Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells. J Virol. 1987 May;61(5):1310–1317. doi: 10.1128/jvi.61.5.1310-1317.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Rowe M., Rowe D. T., Gregory C. D., Young L. S., Farrell P. J., Rupani H., Rickinson A. B. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J. 1987 Sep;6(9):2743–2751. doi: 10.1002/j.1460-2075.1987.tb02568.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Rowe M., Young L. S., Cadwallader K., Petti L., Kieff E., Rickinson A. B. Distinction between Epstein-Barr virus type A (EBNA 2A) and type B (EBNA 2B) isolates extends to the EBNA 3 family of nuclear proteins. J Virol. 1989 Mar;63(3):1031–1039. doi: 10.1128/jvi.63.3.1031-1039.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Sample J., Kieff E. F., Kieff E. D. Epstein-Barr virus types 1 and 2 have nearly identical LMP-1 transforming genes. J Gen Virol. 1994 Oct;75(Pt 10):2741–2746. doi: 10.1099/0022-1317-75-10-2741. [DOI] [PubMed] [Google Scholar]
  36. Sample J., Young L., Martin B., Chatman T., Kieff E., Rickinson A., Kieff E. Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. J Virol. 1990 Sep;64(9):4084–4092. doi: 10.1128/jvi.64.9.4084-4092.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Sculley T. B., Apolloni A., Hurren L., Moss D. J., Cooper D. A. Coinfection with A- and B-type Epstein-Barr virus in human immunodeficiency virus-positive subjects. J Infect Dis. 1990 Sep;162(3):643–648. doi: 10.1093/infdis/162.3.642. [DOI] [PubMed] [Google Scholar]
  38. Sculley T. B., Apolloni A., Stumm R., Moss D. J., Mueller-Lantczh N., Misko I. S., Cooper D. A. Expression of Epstein-Barr virus nuclear antigens 3, 4, and 6 are altered in cell lines containing B-type virus. Virology. 1989 Aug;171(2):401–408. doi: 10.1016/0042-6822(89)90608-9. [DOI] [PubMed] [Google Scholar]
  39. Sculley T. B., Cross S. M., Borrow P., Cooper D. A. Prevalence of antibodies to Epstein-Barr virus nuclear antigen 2B in persons infected with the human immunodeficiency virus. J Infect Dis. 1988 Jul;158(1):186–192. doi: 10.1093/infdis/158.1.186. [DOI] [PubMed] [Google Scholar]
  40. Sixbey J. W., Nedrud J. G., Raab-Traub N., Hanes R. A., Pagano J. S. Epstein-Barr virus replication in oropharyngeal epithelial cells. N Engl J Med. 1984 May 10;310(19):1225–1230. doi: 10.1056/NEJM198405103101905. [DOI] [PubMed] [Google Scholar]
  41. Sixbey J. W., Shirley P., Chesney P. J., Buntin D. M., Resnick L. Detection of a second widespread strain of Epstein-Barr virus. Lancet. 1989 Sep 30;2(8666):761–765. doi: 10.1016/s0140-6736(89)90829-5. [DOI] [PubMed] [Google Scholar]
  42. Sixbey J. W., Shirley P., Sloas M., Raab-Traub N., Israele V. A transformation-incompetent, nuclear antigen 2-deleted Epstein-Barr virus associated with replicative infection. J Infect Dis. 1991 May;163(5):1008–1015. doi: 10.1093/infdis/163.5.1008. [DOI] [PubMed] [Google Scholar]
  43. Thorley-Lawson D. A., Geilinger K. Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity. Proc Natl Acad Sci U S A. 1980 Sep;77(9):5307–5311. doi: 10.1073/pnas.77.9.5307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Tierney R. J., Steven N., Young L. S., Rickinson A. B. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J Virol. 1994 Nov;68(11):7374–7385. doi: 10.1128/jvi.68.11.7374-7385.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Walling D. M., Clark N. M., Markovitz D. M., Frank T. S., Braun D. K., Eisenberg E., Krutchkoff D. J., Felix D. H., Raab-Traub N. Epstein-Barr virus coinfection and recombination in non-human immunodeficiency virus-associated oral hairy leukoplakia. J Infect Dis. 1995 May;171(5):1122–1130. doi: 10.1093/infdis/171.5.1122. [DOI] [PubMed] [Google Scholar]
  46. Walling D. M., Edmiston S. N., Sixbey J. W., Abdel-Hamid M., Resnick L., Raab-Traub N. Coinfection with multiple strains of the Epstein-Barr virus in human immunodeficiency virus-associated hairy leukoplakia. Proc Natl Acad Sci U S A. 1992 Jul 15;89(14):6560–6564. doi: 10.1073/pnas.89.14.6560. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Walling D. M., Perkins A. G., Webster-Cyriaque J., Resnick L., Raab-Traub N. The Epstein-Barr virus EBNA-2 gene in oral hairy leukoplakia: strain variation, genetic recombination, and transcriptional expression. J Virol. 1994 Dec;68(12):7918–7926. doi: 10.1128/jvi.68.12.7918-7926.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Walling D. M., Raab-Traub N. Epstein-Barr virus intrastrain recombination in oral hairy leukoplakia. J Virol. 1994 Dec;68(12):7909–7917. doi: 10.1128/jvi.68.12.7909-7917.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Yao Q. Y., Ogan P., Rowe M., Wood M., Rickinson A. B. Epstein-Barr virus-infected B cells persist in the circulation of acyclovir-treated virus carriers. Int J Cancer. 1989 Jan 15;43(1):67–71. doi: 10.1002/ijc.2910430115. [DOI] [PubMed] [Google Scholar]
  50. Yao Q. Y., Rickinson A. B., Epstein M. A. A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals. Int J Cancer. 1985 Jan 15;35(1):35–42. doi: 10.1002/ijc.2910350107. [DOI] [PubMed] [Google Scholar]
  51. Yao Q. Y., Rowe M., Martin B., Young L. S., Rickinson A. B. The Epstein-Barr virus carrier state: dominance of a single growth-transforming isolate in the blood and in the oropharynx of healthy virus carriers. J Gen Virol. 1991 Jul;72(Pt 7):1579–1590. doi: 10.1099/0022-1317-72-7-1579. [DOI] [PubMed] [Google Scholar]
  52. Yao Q. Y., Rowe M., Morgan A. J., Sam C. K., Prasad U., Dang H., Zeng Y., Rickinson A. B. Salivary and serum IgA antibodies to the Epstein-Barr virus glycoprotein gp340: incidence and potential for virus neutralization. Int J Cancer. 1991 Apr 22;48(1):45–50. doi: 10.1002/ijc.2910480109. [DOI] [PubMed] [Google Scholar]
  53. Yao Q. Y., Tierney R. J., Croom-Carter D., Cooper G. M., Ellis C. J., Rowe M., Rickinson A. B. Isolation of intertypic recombinants of Epstein-Barr virus from T-cell-immunocompromised individuals. J Virol. 1996 Aug;70(8):4895–4903. doi: 10.1128/jvi.70.8.4895-4903.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Young L. S., Yao Q. Y., Rooney C. M., Sculley T. B., Moss D. J., Rupani H., Laux G., Bornkamm G. W., Rickinson A. B. New type B isolates of Epstein-Barr virus from Burkitt's lymphoma and from normal individuals in endemic areas. J Gen Virol. 1987 Nov;68(Pt 11):2853–2862. doi: 10.1099/0022-1317-68-11-2853. [DOI] [PubMed] [Google Scholar]
  55. Young L., Alfieri C., Hennessy K., Evans H., O'Hara C., Anderson K. C., Ritz J., Shapiro R. S., Rickinson A., Kieff E. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med. 1989 Oct 19;321(16):1080–1085. doi: 10.1056/NEJM198910193211604. [DOI] [PubMed] [Google Scholar]
  56. Zimber U., Adldinger H. K., Lenoir G. M., Vuillaume M., Knebel-Doeberitz M. V., Laux G., Desgranges C., Wittmann P., Freese U. K., Schneider U. Geographical prevalence of two types of Epstein-Barr virus. Virology. 1986 Oct 15;154(1):56–66. doi: 10.1016/0042-6822(86)90429-0. [DOI] [PubMed] [Google Scholar]
  57. de Campos-Lima P. O., Levitsky V., Brooks J., Lee S. P., Hu L. F., Rickinson A. B., Masucci M. G. T cell responses and virus evolution: loss of HLA A11-restricted CTL epitopes in Epstein-Barr virus isolates from highly A11-positive populations by selective mutation of anchor residues. J Exp Med. 1994 Apr 1;179(4):1297–1305. doi: 10.1084/jem.179.4.1297. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES